- Home
- TREX vs IONS Comparison
TREX vs IONS Comparison
Compare TREX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TREX
- IONS
- Stock Information
- Founded
- TREX 1996
- IONS 1989
- Country
- TREX United States
- IONS United States
- Employees
- TREX N/A
- IONS N/A
- Industry
- TREX
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- TREX
- IONS Health Care
- Exchange
- TREX Nasdaq
- IONS Nasdaq
- Market Cap
- TREX 6.4B
- IONS 6.8B
- IPO Year
- TREX 1999
- IONS 1991
- Fundamental
- Price
- TREX $58.45
- IONS $61.36
- Analyst Decision
- TREX Buy
- IONS Buy
- Analyst Count
- TREX 14
- IONS 17
- Target Price
- TREX $71.93
- IONS $67.88
- AVG Volume (30 Days)
- TREX 1.4M
- IONS 3.3M
- Earning Date
- TREX 10-27-2025
- IONS 11-05-2025
- Dividend Yield
- TREX N/A
- IONS N/A
- EPS Growth
- TREX N/A
- IONS N/A
- EPS
- TREX 1.73
- IONS N/A
- Revenue
- TREX $1,129,138,000.00
- IONS $944,050,000.00
- Revenue This Year
- TREX $8.91
- IONS $24.30
- Revenue Next Year
- TREX $7.50
- IONS $7.39
- P/E Ratio
- TREX $34.71
- IONS N/A
- Revenue Growth
- TREX N/A
- IONS 16.05
- 52 Week Low
- TREX $49.01
- IONS $23.95
- 52 Week High
- TREX $80.74
- IONS $64.72
- Technical
- Relative Strength Index (RSI)
- TREX 50.29
- IONS 72.44
- Support Level
- TREX N/A
- IONS $60.64
- Resistance Level
- TREX $62.45
- IONS $64.61
- Average True Range (ATR)
- TREX 1.73
- IONS 2.39
- MACD
- TREX -2.55
- IONS 0.67
- Stochastic Oscillator
- TREX 88.47
- IONS 85.24
About TREX Trex Company Inc.
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.